Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.

Sanseviero E, O'Brien EM, Karras JR, Shabaneh TB, Aksoy BA, Xu W, Zheng C, Yin X, Xu X, Karakousis GC, Amaravadi RK, Nam B, Turk MJ, Hammerbacher J, Rubinstein MP, Schuchter LM, Mitchell TC, Liu Q, Stone EL.

Cancer Immunol Res. 2019 Aug;7(8):1371-1380. doi: 10.1158/2326-6066.CIR-18-0386. Epub 2019 Jun 25.

PMID:
31239316
2.

Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis.

Shabaneh TB, Molodtsov AK, Steinberg SM, Zhang P, Torres GM, Mohamed GA, Boni A, Curiel TJ, Angeles CV, Turk MJ.

Cancer Res. 2018 Sep 1;78(17):5038-5049. doi: 10.1158/0008-5472.CAN-18-0365. Epub 2018 Jul 19.

3.

An epoxide hydrolase secreted by Pseudomonas aeruginosa decreases mucociliary transport and hinders bacterial clearance from the lung.

Hvorecny KL, Dolben E, Moreau-Marquis S, Hampton TH, Shabaneh TB, Flitter BA, Bahl CD, Bomberger JM, Levy BD, Stanton BA, Hogan DA, Madden DR.

Am J Physiol Lung Cell Mol Physiol. 2018 Jan 1;314(1):L150-L156. doi: 10.1152/ajplung.00383.2017. Epub 2017 Oct 5.

4.

Resident memory T cells in the skin mediate durable immunity to melanoma.

Malik BT, Byrne KT, Vella JL, Zhang P, Shabaneh TB, Steinberg SM, Molodtsov AK, Bowers JS, Angeles CV, Paulos CM, Huang YH, Turk MJ.

Sci Immunol. 2017 Apr 14;2(10). pii: eaam6346. doi: 10.1126/sciimmunol.aam6346.

5.

Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors.

Steinberg SM, Shabaneh TB, Zhang P, Martyanov V, Li Z, Malik BT, Wood TA, Boni A, Molodtsov A, Angeles CV, Curiel TJ, Whitfield ML, Turk MJ.

Cancer Res. 2017 Apr 1;77(7):1599-1610. doi: 10.1158/0008-5472.CAN-16-1755. Epub 2017 Feb 15.

6.

The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.

Kraus M, Bader J, Geurink PP, Weyburne ES, Mirabella AC, Silzle T, Shabaneh TB, van der Linden WA, de Bruin G, Haile SR, van Rooden E, Appenzeller C, Li N, Kisselev AF, Overkleeft H, Driessen C.

Haematologica. 2015 Oct;100(10):1350-60. doi: 10.3324/haematol.2014.109421. Epub 2015 Jun 11.

7.

BRAF inhibition alleviates immune suppression in murine autochthonous melanoma.

Steinberg SM, Zhang P, Malik BT, Boni A, Shabaneh TB, Byrne KT, Mullins DW, Brinckerhoff CE, Ernstoff MS, Bosenberg MW, Turk MJ.

Cancer Immunol Res. 2014 Nov;2(11):1044-50. doi: 10.1158/2326-6066.CIR-14-0074. Epub 2014 Sep 2.

8.

Acidosis potentiates the host proinflammatory interleukin-1β response to Pseudomonas aeruginosa infection.

Torres IM, Patankar YR, Shabaneh TB, Dolben E, Hogan DA, Leib DA, Berwin BL.

Infect Immun. 2014 Nov;82(11):4689-97. doi: 10.1128/IAI.02024-14. Epub 2014 Aug 25.

9.

Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.

Shabaneh TB, Downey SL, Goddard AL, Screen M, Lucas MM, Eastman A, Kisselev AF.

PLoS One. 2013;8(2):e56132. doi: 10.1371/journal.pone.0056132. Epub 2013 Feb 27.

10.

Discovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones.

van der Linden WA, Willems LI, Shabaneh TB, Li N, Ruben M, Florea BI, van der Marel GA, Kaiser M, Kisselev AF, Overkleeft HS.

Org Biomol Chem. 2012 Jan 7;10(1):181-94. doi: 10.1039/c1ob06554h. Epub 2011 Nov 22.

11.

Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.

Mirabella AC, Pletnev AA, Downey SL, Florea BI, Shabaneh TB, Britton M, Verdoes M, Filippov DV, Overkleeft HS, Kisselev AF.

Chem Biol. 2011 May 27;18(5):608-18. doi: 10.1016/j.chembiol.2011.02.015.

Supplemental Content

Loading ...
Support Center